PROJECT
New Iron Supplement Food Additives and Drugs
The revolutionary iron supplement product that the CBHMC intends to invest in is the invention of the research team from Cambridge University. This product is a new type of nanoparticle structure of iron, which provides optimal safety for the steady-state coupling of the intestinal microbial group; it is an edible "protein iron" which is a non-heme iron that can be naturally digested. This product can be directly released into intestinal cells and effectively absorbed by endocytosis without redox in the intestine, thus preventing common gastrointestinal side effects (iron deficiency, inflammatory bowel syndrome) caused by supplementation of iron products on the market. happened. The market for prescription drugs alone can reach $3.8 billion, while in the food additive market it is more than 2 billion people with iron deficiency worldwide.
Lack of iron can cause anemia, affecting 1.6 billion people worldwide, accounting for 24.5% of the total population. Anemia can lead to impaired cognitive development, poor pregnancy outcomes, increased child morbidity, ill health, fatigue and decreased personal work ability. It is a major risk factor for the global burden of disease (WHO 2017).
Funded by the Melinda Gates Foundation, this product has rescued a large number of patients with various types of iron deficiency in Africa and has accumulated a large amount of clinical data. This new nanoparticulate structure of iron can be used as a food additive and will soon be certified by the EFSA European Food Safety Authority; the product is a revolution in disrupting existing related industries. Its prescription drugs are in clinical trials.
Personalized Cancer Vaccine
The CBHMC intends to finance an investment of approximately 200 million pounds for the equity investment of Company A's personalized cancer vaccine treatment company to support Phase II and Phase III clinical trials and commercial production and sales of 15 cancers. Its personalized cancer vaccine products avoid the huge toxic side effects of current cancer treatment products, maximally activate the body's own immune system, and have remarkable curative effect, suitable for orphan cancer, and various solid tumor cancers and fluid tumor cancers, which are at the FDA. Phase II and III clinical trial indicators, as well as clinical trial indicators for NHS in the UK, are world leaders.
At the same time, for the European market, part of the fund will be invested in the construction of the "Life Science High-Tech Park". Under the participate and guidance of world-class scientists to Create an Integrated Centre in a Large, Campus/Park-like“Green”Setting which Incorporates State-of-the-Art Research Facilities, Bio-manufacturing Facilities, Medical Treatment Facilities, Patient Accommodation and Support Facilities. A Masterplan Designed to Integrate Cutting Edge Research“From Laboratory Bench to Patient Bedside”.This biotechnology center will attract and accommodate the world's most innovative companies in the field.
The medical application of Nitric Oxide
“You have achieved what no-one else has been able to–deliver targeted, high therapeutic amounts of nitric oxide below the dermis.” Dr. Ferid Murad*, 1998 Nobel Prize Winner for his work concerning nitric oxide.
The CBHMC is financing the biotech company to be invested. The patent is based on the results of the 1998 Nobel Prize winner Dr. Ferid Murad. The company's patented gas plasma therapy can provide therapeutic levels for the target area. Nitric oxide. It can improve angiogenesis and condition the inflammatory thorn target area to provide a therapeutic grade of nitric oxide. It can improve blood vessel formation and regulate the target area of the inflammatory thorn to provide therapeutic grade nitric oxide.
The first commercial scenario of its patented products is the huge diabetic foot market in the United States and the world's first treatment for diabetic foot. The 5-year mortality rate for patients with diabetic foot ulcers is about 50%, and the 5-year mortality rate for patients with diabetic foot ulcers after amputation rises to 74% higher than almost all cancer patients except lung cancer and pancreas. China's spending on diabetes care has reached $51 billion / $90 billion international dollars. It is foreseeable that this therapy can be applied in a variety of disease scenarios, with a market size of more than $100 billion, oral treatment ($1 billion); venous leg ulcers ($2 billion); wound care ($16 billion); skin disease (220 US$100 million; antibiotic resistance ($20 billion); skin and soft tissue infections ($14 billion); pain and inflammation ($62 billion).
The first product is already in clinical phase III. The interim data reflects the strong evidence of cure, high safety and clear dose response.“In over 22 years of doing wound care I haven’t seen any product like this plasma-generated nitric oxide therapy before. It’s completely novel and appears to be creating a new way of healing. Once healed you cannot even see where the wound was, it literally looks like new skin” It’s completely novel and appears to be creating a new way of healing. its plasma-generated NO expedited healing 40-50% faster than what I am used to seeing. Some wounds that were two years old closed almost 60% in two-weeks…”
Dr. Anna Sanchez, DPM, Texas. Clinical Investigator
Novel Gastric and Trypsin Resistant Glutathionase
The CBHMC plans to raise 10 million pounds to invest in a new oral enzyme therapy for gluten intolerance.It is used in celiac disease patients with celiac disease and NCGS(non-celiac gluten sensitive) patients. It has been shown to neutralize the negative effects of immune stimulation of intestinal T cells, which respond to gluten and gliadin in gluten resistant patients.This activity is associated with the prevention of intestinal malabsorption and mucosal destruction in celiac disease. Prodromal celiac disease is a severe intestinal autoimmune disease that can occur in people with genetic predisposition but is caused by environmental factors.This happens when people become sensitive to gluten, a substance found in wheat, rye and barley.Their immune system triggers a response to the body's own cells, which damage the mucosal surface of the small intestine.Celiac disease affects about one percent of the population, but the risk is about three times higher in people with cystic fibrosis.
The autoimmune response of a patient after eating gluten can cause damage to a variety of organs and tissues, including the intestines, liver, uterus, joints, skin, and brain. Therefore, celiac disease patients often not only have abdominal pain, bloating, diarrhea, constipation and other gastrointestinal symptoms, but also fibromyalgia, osteoporosis, elevated alanine aminotransferase, herpes-like dermatitis, malnutrition, depression, anxiety, anemia Extraintestinal symptoms such as small intestinal lymphoma. The risk of cancer in patients with celiac disease is almost twice that of the average person.Compared with the general population, patients with CD are many times more likely to develop adenocarcinoma of the small intestine (a rare cancer).There is also the t-cell lymphoma associated with bowel disease, which occurs in adults, 70 to 80 years of age appear peak incidence, diagnosis is usually late.
There are 5 million diagnosed patients in the UK, but in China“the domestic understanding of celiac disease (CD) is not sufficient, and the number of confirmed cases is extremely limited, but many cases are just the tip of the iceberg – covered in functional dyspepsia Or Irritable Bowel Syndrome (IBS) and other diagnoses, the symptoms of IBS and CD are often crossed, but the treatment plan and prognosis are very different."----Xia Wei, Chief Physician, Department of Gastroenterology, Shanghai International Medical Center。
The fund will also invest in a "oral enzyme" hydrogel delivery system whose function is to provide a once-a-day gradual release of active enzyme dose into the duodenum.